FDA evaluation of coal tar warnings
This article was originally published in The Rose Sheet
Presence of cancer warnings on some dandruff, psoriasis OTCs "may render the products misbranded," and FDA is "evaluating the complex issues raised" by such cautions, agency says in recent letter to Alva-Amco counsel Bell, Boyd & Lloyd (Chicago). Law firm had requested FDA determine whether Prop 65 cancer warnings found on some OTC coal tar medications - including Alva-Amco's Psoriasin Gel, GlaxoSmithKline/Block Drug's Tegrin, Medtech's Oxipor - constitute misbranding. Agency's February decision that additional warnings are not required on such products did not address whether inclusion of Prop 65 statement would misbrand them (1"The Rose Sheet" March 5, p. 8). Prop 65 lawsuit against Alva-Amco, other coal tar product makers is set for trial in January...
You may also be interested in...
STADA Strengthens Specialty Partnership Role Via US Filing
Antoine Marchal, Franchise Head PCR Core Labs - BA Molecular Diagnostics at Qiagen outlines how NeuModx will strengthen its position in the infectious disease space.
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.